Market Overview

UPDATE: Rodman & Renshaw Downgrades Zalicus to Market Perform on Synavive Failure


Rodman & Renshaw reduced its rating on Zalicus (NASDAQ: ZLCS) from Market Outperform to Market Perform and suspended its previous $5 price target.

Rodman & Renshaw noted, "Yesterday, Zalicus (ZLCS) announced that Synavive failed to demonstrate clinically meaningful benefit compared to its active glucocorticoid component, prednisolone 2.7mg. As a result, the company will discontinue the program. According to our investment policy, we are changing our Under Review to Market Perform without a Target Price for Zalicus shares. We are also removing all estimates from our model for Synavive, which previously had accounted for $2.01 towards our SOTP (sum of the parts) valuation analysis."

Zalicus closed at $0.79 on Monday.

Latest Ratings for ZLCS

Nov 2013DowngradesOutperformNeutral
Nov 2013DowngradesOutperformPerform
Oct 2012DowngradesHoldSell

View More Analyst Ratings for ZLCS
View the Latest Analyst Ratings

Posted-In: Rodman & RenshawAnalyst Color Downgrades Intraday Update Analyst Ratings


Related Articles (ZLCS)

View Comments and Join the Discussion!

Latest Ratings

HUBBInitiates Coverage On160.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

General Dynamics Wins $42M Contract

UPDATE: Global Hunter Securities Downgrades Plains Exploration & Production to Accumulate